Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK2 | Q16620 | 4/20 | 0.66 |
| ▸ | CSF1R | P07333 | 6/20 | 0.65 |
| ▸ | KDR | P35968 | 8/20 | 0.63 |
| ▸ | PRKAA1 | Q13131 | 7/20 | 0.63 |
| ▸ | PRKAA2 | P54646 | 5/20 | 0.63 |
| ▸ | PDGFRB | P09619 | 5/20 | 0.60 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.60 |
| ▸ | NTRK1 | P04629 | 5/20 | 0.60 |
| ▸ | FLT3 | P36888 | 4/20 | 0.60 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.59 |
| ▸ | NTRK3 | Q16288 | 3/20 | 0.58 |
| ▸ | EGFR | P00533 | 3/20 | 0.58 |
| ▸ | PLK4 | O00444 | 2/20 | 0.58 |
| ▸ | DCLK1 | O15075 | 2/20 | 0.58 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.58 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.58 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.58 |
| ▸ | RPS6KA5 | O75582 | 2/20 | 0.58 |
| ▸ | RPS6KA4 | O75676 | 2/20 | 0.58 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10091898 | 1.00 | NTRK2 (0.66) | NTRK2CSF1RKDRPRKAA1PRKAA2 | |
| SCHEMBL395944 | 0.97 | CSF1R (0.69) | NTRK2CSF1RKDRPRKAA1PRKAA2 | |
| SCHEMBL10091859 | 0.97 | CSF1R (0.69) | NTRK2CSF1RKDRPRKAA1PRKAA2 | |
| SCHEMBL10091905 | 0.94 | CSF1R (0.62) | NTRK2CSF1RKDRPRKAA1PRKAA2 | |
| SCHEMBL397867 | 0.94 | CSF1R (0.62) | NTRK2CSF1RKDRPRKAA1PRKAA2 | |
| SCHEMBL10091899 | 0.93 | NTRK2 (0.73) | NTRK2CSF1RKDRPRKAA1PRKAA2 | |
| SCHEMBL397946 | 0.93 | NTRK2 (0.73) | NTRK2CSF1RKDRPRKAA1PRKAA2 | |
| SCHEMBL10091894 | 0.91 | KDR (0.69) | NTRK2CSF1RKDRPRKAA1PRKAA2 | |
| SCHEMBL396849 | 0.91 | KDR (0.69) | NTRK2CSF1RKDRPRKAA1PRKAA2 | |
| SCHEMBL10091852 | 0.90 | NTRK2 (0.67) | NTRK2CSF1RKDRPRKAA1PRKAA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101608-B2 | 3-(4-Methyl-imidazol-1-yl)-N-{3-[2-oxo-3-(1H-pyrrol-2-ylmethylene)-2,3-dihydro-1H-indol-6-ylamino]-phenyl}-5-trifluoromethyl-benzamide; including benign and malignant proliferative disorders as well as diseases resulting from inappropriate activation of the immune and nervous systems | IRM LLC, a Delware Limited Corporation (BM) | 2012-01-24 | — | — | US | claimed |
| US-20080221192-A1 | Compounds and Compositions as Protein Kinase Inhibitors | IRM LLC (BM) | 2008-09-11 | — | — | US | claimed |
| US-8101608-B2 | 3-(4-Methyl-imidazol-1-yl)-N-{3-[2-oxo-3-(1H-pyrrol-2-ylmethylene)-2,3-dihydro-1H-indol-6-ylamino]-phenyl}-5-trifluoromethyl-benzamide; including benign and malignant proliferative disorders as well as diseases resulting from inappropriate activation of the immune and nervous systems | IRM LLC, a Delware Limited Corporation (BM) | 2012-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221192-A1 | Compounds and Compositions as Protein Kinase Inhibitors | BMX, FRK, PTK2B | NTRK2 235/4885CSF1R 796/4885KDR 204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.